January 27-29, 2026 | Boston, MA
www.rnaibased-therapeutics.com

REGISTER BY NOVEMBER 7 & SAVE UP TO $700

WELCOME
EXPERT SPEAKERS
AGENDA
PARTNER WITH US
REGISTER YOUR PLACE

7th Annual

RNAi-Based Therapeutics Summit

Translating Novel siRNA & microRNA Drugs from Bench to Bedside

Discover, Develop & Selectively Deliver Highly Stable & Potent RNAi Therapeutics for Targeted & Effective Gene Silencing in Oncology, Rare, Cardiovascular Disorders & Beyond

Expert Speakers Include:

James Carroll
President & Chief Executive Officer
RNA NanoBiotics

Anthony Saleh
Chief Executive Officer
miRecule

Raj Reddy
Chief Executive Officer
Canary Cure

Paul Lawrence
Executive Director of Bioscience Research, Discovery, & Scientific Communications
Biocogent

Andrew Coles
Senior Scientist
AbbVie

Alfica Sehgal
Chief Scientific Officer
Judo Biosciences

Proud to Partner With:

SynOligo BIOTECHNOLOGIES
CHEMGENES
sylentis CDMO

+1 617 455 4188 info@hansonwade.com
www.rnaibased-therapeutics.com World RNA Series

hansonwade

The Industry-Dedicated Forum for RNAi Therapeutics

7th Annual RNAi-Based Therapeutics Summit
January 27-29, 2026 | Boston, MA

2025 has already proven to be a landmark year, marked by Sanofi and Alnylam's first RNAi therapeutic approval for hemophilia, Along with Arrowhead's advancement in Phase II candidates against obesity, and Biogen's monumental $1bn partnership with City Therapeutics for neurological disorders. **This surge of progress signals a pivotal industry inflection point: RNAi is decisively moving beyond the liver, validating the modality's potential across a vast spectrum of diseases**.

The timing is perfect for the **7th RNAi-Based Therapeutics Summit** to returns to Boston in January 2026. This is the essential forum for stakeholders across pharma, biotech, VC, and vendors to decode these successes, translate them into actionable strategies, and collectively tackle the remaining hurdles in delivery, development, and manufacturing.

Join us as we explore the field's most pressing questions to accelerate the next chapter of transformative patient treatments. Key discussions include:

- Address your burning challenges including: Improving RNAi delivery beyond the liver using **aptamers**, **peptide conjugates**, **bispecifics**, or non-LNP strategies for **extrahepatic targeting**
- **Uncovering novel strategies to validate RNAi targets in complex diseases outside of liver** like rare disorders and cardiovascular conditions
- **Enhancing RNAi drug purity** and **stability**, as well as **reduce off-target effects**, and **optimize dosing** using complex chemistries or siRNA/microRNA combinations
- Understanding **regulatory** and **CMC challenges**, like complex synthesis, model reliability, or CDMO selection, must be overcome to progress RNAi drugs in late-stage clinical development and into the hands of the patients?
- Exploring how can RNAi be effectively integrated with radiotherapy, chemotherapeutics, or precision medicine to boost efficacy and broaden clinical application

Whether you're navigating discovery to IND-enabling studies, tackling clinical development, or strategizing for approval, this is your opportunity to join forces with Senior Scientists, Heads, Directors and C-level decision makers in Discovery, Preclinical, Chemistry, Molecular Biology and CMC to benchmark, collaborate, and shape the next wave of RNAi breakthroughs for the patients in need.

Hear From Our Experts:

"The talks are incredible, very informative and cutting edge"

Kimberley McCarthy, Senior Scientist III, **AbbVie, 6th RNAi-Based Therapeutics Summit**

"Learn the most advanced development progress and communicate with other research on RNAi field"

Jun Li, Senior Director, Innovent Biologics, **6th RNAi-Based Therapeutics Summit**

Key Benefits of Attending

Engineer next-generation delivery platforms for RNAi-based therapies using aptamers, bispecifics, and non-LNP strategies to overcome the final frontier of extrahepatic targeting in muscle, and cardiac tissues, with exclusive data from leaders at **RNA NanoBiotics**, and **Gensaic**

Break through the blood-brain barrier with Trojan Horse formulations, intrathecal delivery, and exosome-mediated strategies to unlock transformative RNAi treatments for Huntington's, Parkinson's, and Epilepsy, leveraging clinical insights from **Ophidion**

Expand your pipeline beyond the liver into obesity, sarcopenia, and cardiac fibrosis with dual-targeting siRNA and novel conjugates, gaining proof-of-concept from preclinical and clinical data on durable, tissue-specific silencing for targeted delivery and translational de-risking, with **Canary Cure**, and **Sangene Bio**

Explore novel applications of RNAi in anti-aging and oncology by leveraging multi-target cocktails and tumor-homing delivery systems to disrupt disease pathways and overcome treatment resistance, with pioneering insights from **Biocogent** and **Judo Biosciences**

Harness the power of AI and computational modeling for RNAi target discovery, predicting off-target effects, and designing self-assembling nanostructures to accelerate lead candidate selection and optimize potency, with cutting-edge tools from **RNatives**, **Gensaic**, and **RNA NanoBiotics**

What's New For 2026?

7th Annual RNAi-Based Therapeutics Summit
January 27-29, 2026 | Boston, MA

20 C-level Speakers

14 New Companies

11 Extrahepatic Delivery Focused Talks

1 Investment Focused Panel

8+ Hours of Meaningful Networking

Key Sessions Not to Miss

Opening the Summit, Dr. Lawrence will present a keynote on using RNAi for anti-aging. He will explore how multi-target RNAi cocktails and topical delivery vehicles can revolutionize skincare and aesthetic treatments.

Paul Lawrence, Executive Director, **Biocogent**

1

Andrew Coles will address applying RNAi to complex conditions like immunology and fibrosis. His session covers engineering targeted LNPs and optimizing siRNA delivery for improved therapeutic responses.

Andrew Coles, Senior Scientist, **AbbVie**

2



Dr. Tsedev will present an AI-designed, dual-targeting siRNA therapeutic for sarcopenia. This novel approach enables precise delivery to muscle tissue, showing significant functional recovery in models.

Uyanga Tsedev, Chief Scientific Officer, **Gensaic**

3

James Carroll will explore self-assembling RNA nanostructures for precision delivery. Learn how programmable RNA origami acts as a nanocarrier to improve tissue-specific payload delivery.

James Carroll, President & CEO, **RNA NanoBiotics**

4

Weimin Wang will share insights on using LEAD™ RNAi technology to treat obesity and metabolic disease. He will present data on this approach for creating durable, tissue-specific therapies.

Weimin Wang, Founder & CEO, **Sangene Bio**

5

Dr. Sehgal will showcase a targeted approach for renal diseases using the STRIKE™ platform. This technology uses ligand-siRNA conjugates for precise kidney cell uptake with minimal systemic exposure.

Alfica Sehgal, Chief Scientific Officer, **Judo Biosciences**

6

New Companies for 2026

Biocogent | RNA NanoBiotics | GenKardia | abbvie | SBP Sebastian Bio Pharma

+1 617 455 4188 info@hansonwade.com
www.rnaibased-therapeutics.com World RNA Series
hansonwade

2026 Expert Speakers

Andrew Coles
Senior Scientist
AbbVie

Andrew Fraley
Partner
Sunrise Bioventures

Alfica Sehgal
Chief Scientific Officer
Judo Biosciences

Anthony Saleh
Chief Executive Officer
miRecule

Audrey Bernstein
Chief Scientific Officer
DUB Therapeutics

Claire Zeng
Chief Executive & Technology Officer
DoriNano

David Jackson
Chief Executive Officer
Ceria Therapeutics

David Zebrowski
Founder & Chief Executive Officer
GenKardia

Greta Garrido
Co-Founder & Chief Executive Officer
Sebastian Biopharma

James Carroll
President & Chief Executive Officer
RNA NanoBiotics

Jingfang Ju
Professor & Founder
iNanoRNA Therapeutics

Joe Nabhan
Chief Scientific Officer
K2B Therapeutics



Jonathan Hsu
Co-Founder & Chief Technology Officer
Gensaic

Julia Alterman
Assistant Professor
UMass Medical School

Lavi Erisson
Co-Founder & Chief Executive Officer
Gensaic

Mikko Turunen
Chief Scientific Officer
RNatives

Muthiah Manoharan
Senior Vice President
Alnylam Pharmaceuticals

Paul Lawrence
Executive Director of Bioscience Research, Discovery, & Scientific Communications
Biocogent



Raj Reddy
Chief Executive Officer
Canary Cure

Tere Williams
Chief Executive Officer
DUB Therapeutics

Uyanga Tsedev
Co-Founder & Chief Scientific Officer
Gensaic

Weimin Wang
Founder & Chief Executive Officer
Sangene Bio

Yacoub Habib
Chief Executive Officer
Ophidion

Yaniv Erlich
Chief Executive Officer
Eleven Therapeutics

Zdravka Medarova
Co-Founder & Chief Technology Officer
TransCode Therapeutics

Pre-Conference Workshop Day
Tuesday, January 27, 2026

Check in & Light Breakfast 8.00

Workshop A 9.00

Understanding RNAi Therapeutic Chemical Engineering to Enhance Extrahepatic Delivery for Improved Therapeutic Outcomes

Chemical engineering of RNAi therapeutics is pivotal for expanding their delivery beyond the liver, to tissues like the CNS, muscle, and eye. Attendees will gain insights into optimizing RNAi constructs for improved stability, potency, and delivery efficiency, bridging the gap between preclinical promise and clinical success. A must-attend for researchers aiming to unlock the full potential of RNAi in extrahepatic applications by discussing:

- Incorporating phosphorothioate and 2-modifications to boost siRNA nuclease resistance, enabling prolonged activity in extrahepatic tissues
- Designing lipid-conjugated siRNAs for enhanced cellular uptake without carriers, simplifying delivery to challenging targets like skeletal muscle or the eye
- Tailoring hydrophobicity and charge to optimize biodistribution and endosomal escape, maximizing target gene knockdown in non-liver organs

Workshop Leaders:

David Jackson
Chief Executive Officer
Ceria Therapeutics

Claire Zeng
Chief Executive & Technology Officer
DoriNano

Lunch Break & Networking 12.00

Workshop B 13.00

Maximizing Novel *In Silico* Strategies to Harness Data-driven Approaches for the Development & Delivery of RNAi-based Therapeutics

The rapid evolution of in silico tools is revolutionizing RNAi therapeutic development, from target discovery to regulatory approval. Attendees will learn how to leverage these tools to expand RNAi applications beyond current frontiers, optimize drug stability, and navigate regulatory hurdles. A must for teams aiming to harness data-driven approaches for faster, smarter RNAi therapeutic design. Discussion highlights include:

- Deploying AI-powered genomic and transcriptomic analysis to uncover high-confidence RNAi targets, and directed evolution-based discovery of novel protein-to-protein interactions governing tissue-selective, extrahepatic delivery of siRNA.
- Applying machine learning to predict off-target effects and potency, streamlining lead candidate selection, and reducing late-stage attrition in preclinical development
- Utilizing computational modelling to connect sequence and structure with functional data layers, such as predicting ligands for orphan receptors, binding affinity, internalization dynamics and stability, to accelerate discovery and translation of early leads.

Workshop Leaders:

Mikko Turunen
Chief Scientific Officer
RNatives

Jonathan Hsu
Chief Technology Officer
Gensaic

Conference Day One
Wednesday, January 28, 2026

7.30 **Check in & Light Breakfast**

Mauricio Garcia-Atance
Program Director
Hanson Wade

8.20 **Program Director's Opening Remarks**

8.25 **Chair's Opening Remarks**

Entering the RNAi-Based Therapeutics Revolution to Treat Symptoms & Reprogram their Cause

Paul Lawrence
Executive Director of Bioscience Research, Discovery, & Scientific Communications
Biocogent

8.30 **Reversing Time: Exploring the Utility of RNAi for Anti-Aging Applications**

- Evaluating multi-target RNAi cocktails to modulate inflammatory and aging pathways, offering personalized skincare solutions
- Using topical delivery vehicles enhance skin penetration, enabling non-invasive treatment of wrinkles and other aspects of aging
- Demonstrating the Paradigm shift that RNAi-Based Therapies Can Be for Modern Skin Health Applications

Expanding Horizons in RNAi Therapeutics to Develop Medicines for Systemic & Extrahepatic Diseases

Raj Reddy
Chief Executive Officer
Canary Cure

9.00 **Beyond Appetite: Extrahepatic RNAi to Transform Obesity & Metabolic Disease – Dual siRNA Reprogramming Fat for Durable, Muscle-Enhancing Weight Loss**

- Exploring advances in extrahepatic dual RNAi delivery to enable targeted delivery to adipose tissue for treating the root cause of metabolic disease
- Demonstrating preclinical efficacy through human adipocyte validation to provide robust proof-of-concept and de-risk clinical translation
- Discussing how dual-target RNAi can expand beyond obesity into MASLD/MASH and cardiometabolic health to systemically improve metabolic parameters
- Positioning multi-target RNAi as the next wave beyond appetite suppression to move beyond the limitations of central appetite suppression and offer a more durable, tissue-specific, and holistic solution for sustainable weight loss

Uyanga Tsedev
Chief Scientific Officer
Gensaic

9.30 **Engineering a Dual-Targeting siRNA Therapeutic with AI-Designed Ligands to Treat the Underlying Biology of Sarcopenia**

- Introducing a novel protein-conjugated siRNA modality for muscle that enables targeted delivery to skeletal muscle to overcome limitations of current antibody-based inhibitors, while avoiding off-target tissues
- Leveraging dual-targeting to silence redundant nodes in the inhibitory signalling pathway of muscle growth, moving beyond single-target inhibition to achieve functional recovery
- Demonstrating in vivo delivery, potent target knockdown, and significant functional improvement in models of muscle wasting

David Zebrowski
Founder & Chief Executive Officer
GenKardia

10.00 **Targeting Gene Regulators of Cardiomyocyte Disfunction: A New RNAi Paradigm for Heart Failure**

- Leveraging highly specific RNAi therapeutics, directly silencing key myocardial genes, to halt the underlying disease progression and move beyond symptom management
- Utilizing a novel, targeted delivery platform, enabling efficient extrahepatic delivery to cardiac tissue, to achieve robust efficacy and open new treatment possibilities for patients
- Addressing the root cause of cardiomyocyte disfunction to restore cardiac function and significantly improve patient quality of life

Conference Day One
Wednesday, January 28, 2026

10.30 Speed Networking
Put a face to a name: this session is the perfect opportunity to get face-to-face time with key opinion leaders, leading companies, and innovative researchers in the RNAi-based therapeutics field. Establish meaningful connections to build upon for the rest of the conference and gain individual insight beyond the papers and press releases into pioneering research and technique applications.

11.00 Morning Break

Silencing the Drivers of Fibrosis: From Systemic Challenges to Precision Therapies

Andrew Coles
Senior Scientist
AbbVie

11.30 Examining the Common Challenges of RNAi Therapies in Immunology and Fibrosis to Improve Targeted Delivery and Increase Biodistribution
- Engineering immune cell and fibroblast-targeted LNPs or antibodies to deliver RNAi payloads, reducing cytokine-driven inflammation in autoimmune disorders
- Co-administering siRNA to produce better a therapeutic response
- Optimizing biodistribution for fibrotic tissues via novel chemistries, reversing organ fibrosis with localized effects

Julia Alterman
Assistant Professor
UMass Medical School

12.00 A combinatorial, Unimolecular siRNA Approach for the Treatment of Fibrodysplasia Ossificans Progressiva
- Novel Hydrophobic divalent architecture for delivery to the muscle
- Allele specific targeting with siRNAs
- Prevention of severe disease phenotype in mouse model of FOP

Audrey Bernstein
Chief Scientific Officer
DUB Therapeutics

12.30 Leveraging an RNAi Solution for a Novel Integrin in Chronic Fibrosis
- Leveraging self-delivering siRNA technology to silence a novel integrin target that drives the pathological switch to chronic fibrosis
- Unlocking regenerative healing by reversing myofibroblast persistence
- Validating a new treatment paradigm to demonstrate potent target knockdown and functional recovery in models of fibrotic disease

13.00 Lunch & Networking

Paradigm Shifts: Applying RNAi to Chemo-Resistance and Heart Failure

Jingfang Ju
Professor & Founder
iNanoRNA Therapeutics

14.00 Highlighting miRNA's Increased Oncological Efficiency in Treating Chemotherapy-Resistant Cancers
- Exploiting multi-gene silencing by miRNA to disrupt cancer pathways, overcoming chemo-resistance in aggressive tumours
- Deploying tumour-homing vehicle free delivery for precise miRNA uptake, sparing healthy tissues and reducing toxicity
- Showing high safety and activity in Phase I clinical trials with miRNA-15a positioning it as a first-in-class oncology RNAi drug

Zdravka Medarova
Co-founder & Chief Technology Officer
TransCode Therapeutics

14.30 Testing Novel Drug Design Engines for Cancer for Improved Efficacy and Toxicity Mitigation
- Exploring the challenges of delivering RNAi to cancer
- Evaluating potential strategies to enable the development of RNAi-based drugs
- Presenting examples of emerging RNAi-based therapeutics for cancer

Conference Day One
Wednesday, January 28, 2026

Breaking Barriers in RNAi Delivery to the Brain & CNS: From Innovation to Clinical Translation

15.00 **Overcoming the Blood-Brain Barrier Challenge on the Trojan Horse**

Yacoub Habib
Chief Executive Officer
Ophidion Inc

- Utilizing the advanced Trojan Horse formulations to enhance blood-brain barrier penetration, enabling systemic delivery of RNAi therapeutics for neurodegenerative diseases with gain in function
- Engineering receptor-mediated transcytosis to selectively transport siRNA and ASOs into the CNS, reducing off-target effects and improving therapeutic precision
- Demonstrating preclinical efficacy with a primary focus on Huntington's disease, achieving significant knockdown of huntingtin protein and paving a clear path toward clinical development for severe neurological disorders

15.30 **Afternoon Break & Poster Session**

Connect with peers in a relaxed atmosphere and continue to forge new and existing relationships while exploring the latest in RNAi-based therapies and research advancements.

To submit a poster, please contact info@hansonwade.com

Optimizing RNAi Therapeutics for Advanced CMC & Formulation Strategies Streamline Scale-Up and Manufacturing

16.30 **Engineering Self-Assembling RNA NanoStructures for Improved Precision Delivery in RNAi Therapeutic Delivery**

James Carroll
President & Chief Executive Officer
RNA NanoBiotics

- Developing programmable RNA origami structures that self-assemble into precise nanocarriers enabling tissue-specific delivery with reduced off-target effects
- Incorporating conditional stability triggers that respond to cellular microenvironment cues for controlled payload release at disease sites
- Demonstrating encapsulation efficiency through optimized nanostructure design significantly improving therapeutic payload delivery

Understanding Investor Insights to Define Success in RNAi Therapeutics for de-risking development strategies

17.00 **Panel Discussion: Understanding RNAi Therapeutic Insights from Investors to Identify High-Value Assets and Maximizing Investment Returns**

The RNAi therapeutics landscape is rapidly evolving, with breakthroughs in delivery, efficacy, and commercialization reshaping investor expectations. Key discussion points will include clinical differentiation, market potential, and exit strategies, offering a reality check on valuation drivers and red flags.

- Prioritizing delivery platform versatility as a key value driver, enabling investors to back RNAi companies with broad therapeutic applicability
- Assessing clinical milestones beyond knockdown efficiency, including durability and patient-centric endpoints, to identify therapies with superior commercial potential
- Balancing platform validation with indication selection for optimal risk/reward, ensuring portfolio companies can attract pharma partnerships or IPO success

James Carroll
President & Chief Executive Officer
RNA NanoBiotics

Lavi Erisson
Chief Executive Officer
Gensaic

Andrew Fraley
Founding and Managing Partner
Sunrise Bioventures

Tere Williams
Chief Executive Officer
DUB Therapeutics

17.30 **Chair's Closing Remarks & End of Conference Day One**

Conference Day Two
Thursday, January 29, 2026

7.30 **Check in & Light Breakfast**

8.20 **Chair's Opening Remarks**

Examining Innovative Delivery Strategies to Expand RNAi Therapeutic Applications for Enhanced Tissue Specific Targeting

Weimin Wang
Founder & Chief Executive Officer
Sangene Bio

8.30 **Utilizing LEAD™ RNAi Technology to Treat Obesity and Metabolic Disease**

- Novel ligand-mediated approaches for selectively targeting adipocytes, muscle, and other metabolic compartments are needed to realize the potential of RNAi for obesity therapy
- LEADTM technology is a new ligand-and-enhancer conjugation approach that enables improved specificity and potency for obesity targets across multiple biological mechanisms
- In this presentation, we will share clinical and preclinical data demonstrating the potential for best-in-class RNAi payloads, differentiated pharmaceutical properties, and therapeutic proof-of-concept to treat obesity and metabolic disorders

Yaniv Erlich
Chief Executive Officer
Eleven Therapeutics

9.00 **DELiveri®: discovering cell specific delivery molecules for RNAi using high throughput screens with millions of conjugates**

- Exploring the role of DELiveri® as a powerful product engine to enable functional screens of millions of delivery molecules in human cells in a one-pot reaction, for improved specificity of RNAi therapies
- Evaluating the quantitative output of the screen, providing a score for each molecule, and setting the basis to train AI algorithms
- Sharing insights from over 30 screens conducted across multiple primary human cell types, along with in-vivo validation data for novel compounds, to establish a robust predictive framework for translating in vitro results into effective in vivo therapies

David Jackson
Chief Executive Officer
Ceria Therapeutics

9.30 **Leveraging a Novel RNAi Delivery Platform and Strategy for Extrahepatic Targeted Therapy**

- Exploiting a novel RNAi delivery modality due to unique uptake and release kinetics for the development of acute RNAi therapeutics
- Leveraging direct tissue targeting of RNAi therapeutics to unlock previously inaccessible conditions for improved therapeutic outcomes
- Using selective translational models to derisk RNAi therapeutic development for pipeline acceleration

Claire Zeng
Chief Executive & Technology Officer
DoriNano

10.00 **Exploring DNA Origami-Assisted siRNA Delivery**

- Engineering multi-valent delivery vehicles to optimize cellular uptake and endosomal escape to avoid the limitations of conventional lipid nano particles
- Leveraging programmable nanoscale architecture and enabling modular assembly of nano particles for precision delivery of siRNa Payloads
- Demonstrating potent efficacy of DNA origami-siRNA constructs in preclinical models of disease

Mano Manoharan
Senior Vice President, Innovation Chemistry
Alnylam Pharmaceuticals

10.30 **Transcending GalNAc Conjugates Through Chemical Modifications for Enhanced Delivery, Safety and Efficacy of RNAi Therapeutics**

- Leveraging advanced chemical modifications to develop novel conjugate platforms, to enable delivery beyond the liver with high specificity, to expand treatable diseases to include neurological disorders and rare cancers
- Applying bespoke chemical modifications to peptide-based and other conjugate systems to improve endosomal escape and intracellular siRNA bioavailability to boost gene silencing efficacy while reducing dose frequency and toxicity
- Implementing a next-generation, data-rich platform for the rapid design and optimization of novel ligand-siRNA chemistries to accelerate optimization of delivery chemistries for unmet clinical needs, for future-proofing Alnylam's pipeline against GalNAc's limitations

11.00 **Morning Break & Networking**

Conference Day Two
Thursday, January 29, 2026

11.30 **Leveraging the STRIKE™ Platform for Targeted and Specific Gene Silencing Kidneys for Systemic Diseases**

Alfica Sehgal
Chief Scientific Officer
Judo Biosciences

- Understanding how the STRIKE™ platform utilizes proprietary ligand-siRNA conjugates (STRIKERs) for precise, receptor-mediated uptake in target kidney cells, minimizing systemic exposure and off-site toxicity.
- Exploring how megalin-STRIKERs are engineered to enhance cellular internalization into proximal tubule cells, improving the efficiency of gene silencing
- Evaluating how this targeted delivery approach enables potent and durable silencing, providing a long-term therapeutic strategy

12.00 **Expanding RNAi Delivery to Muscle Tissue Through Antibody Oligonucleotide Conjugates**

Anthony Saleh
Chief Executive Officer
miRecule

- Antibody-siRNA conjugates enable muscle-selective uptake, treating myopathies with minimal off-target effects
- Enhanced endosomal escape increases cytoplasmic siRNA release, improving dystrophin restoration in Duchenne MD
- Modular platform allows rapid re-targeting, accelerating therapies for multiple rare muscle disorders

12.30 **Roundtable Discussion: The Delivery Playbook: Integrating Novel Platforms, Chemistries, and Targeting Ligands for Widespread Extrahepatic Impact**

The breakthroughs in RNAi delivery are no longer confined to the liver, with a new generation of platforms, from antibody conjugates and DNA nanostructures to novel ligands and chemical modifications, enabling precise targeting of metabolic, muscular, and renal tissues. This roundtable unites pioneers to discuss:

- Weighing the advantages of modular platforms against bespoke conjugate strategies for specific tissue targets, considering factors like valency, manufacturability, and immunogenicity.
- Addressing the unique synthesis, characterization, and manufacturing challenges of complex delivery modalities to ensure quality, stability, and scalability for clinical and commercial supply.
- Strategizing on how to design platforms with inherent adaptability to rapidly retarget new tissues and diseases, maximizing platform value and accelerating development timelines.
- n selection for optimal risk/reward, ensuring portfolio companies can attract pharma partnerships or IPO success

David Jackson
Chief Executive Officer
Ceria Therapeutics

Claire Zeng
Chief Executive & Technology Officer
DoriNano

Weimin Wang
Founder & Chief Executive Officer
Sangene Bio

13.00 **Lunch & Networking**

Engineering Specificity & Safety Through the Chemical Biology and Pharmacology of RNAi-Based Therapies

14.00 **Targeted Delivery of RNAi Therapeutics Using a Tumor Directed Protein Fragment**

Joe Nabhan
Chief Scientific Officer
K2B Therapeutics

- Featuring a proprietary tumor-directed protein, which mediates potent and selective biodistribution to tumors, as validated by higher payload concentration
- Demonstrating efficient functional delivery in vitro and in vivo of siRNA molecules to cancer cells for therapeutic application, achieving robust oncogene silencing and a profound anti-tumor effect
- Exploring the utility of siRNA delivery as an adjunct therapy to drug conjugates to sequentially disrupt oncogenic pathways and eradicate tumor cells, thereby overcoming mechanism-based resistance

Conference Day Two
Thursday, January 29, 2026

14.30 Reprogramming Tumor Antigenicity & Enhancing Immunotherapy Responsiveness with an Antibody-Targeted RNAi Platform

Greta Garrido
Cofounder & Chief Executive Officer
Sebastian Biopharma

- Showcasing early preclinical evidence of tumor-selective siRNA activity with minimized off-target effects through aptamer-based targeting
- Introducing the Antibody-Oligonucleotide Conjugate (AOC) platform and proof-of-concept studies validating precision tumor delivery
- Presenting data from lead candidate selection and in-depth characterization to demonstrate potency and durability
- Exploring future opportunities to integrate Sebastian BioPharma's RNAi platforms with checkpoint inhibitors and precision medicine strategies to expand patient benefit

15.00 Roundtable Discussion: The Molecular Toolbox: Optimizing Chemistries, Conjugates, and Payloads for Safer, More Precise RNAi Drugs

The therapeutic window of RNAi is defined by the intricate balance between potent silencing and off-target effects, driven by advances in chemical modifications, novel conjugate strategies, and a deeper understanding of RNAi pharmacology. This roundtable convenes experts pioneering these chemical and biological innovations to define the principles for building better, safer RNAi therapeutics by discussing:

- How are novel phosphorothioate patterns, 2'-modifications, and scaffold designs being used to actively direct biodistribution, improve cellular uptake, and facilitate endosomal escape
- Comparing the advantages, limitations, and unique pharmacological profiles of emerging delivery vehicles.
- Integrating predictive tools for immunogenicity and off-target effects early in candidate selection.

Joe Nabhan
Chief Scientific Officer
K2B Therapeutics

Greta Garrido
Cofounder & Chief Executive Officer
Sebastian Biopharma

The Future of RNAi: Integrating with Precision Medicine for Targeted, High-Impact Therapies

15.30 Panel Discussion: Looking into the Future of RNAi & Precision Medicine Through Synergizing AI, Combination Therapies & Multi-Target Silencing for Next-Generation Treatments

The future of RNAi lies at the intersection of precision medicine, AI-driven innovation, and strategic combination approaches. This panel explores how integrating cutting-edge technologies like AI target discovery with synergistic modalities can unlock new therapeutic potential. Experts will discuss multi-target silencing strategies, new target molecule classes, and how to future-proof RNAi pipelines to lead the next wave of transformative treatments. Join us to gain actionable insights on positioning your RNAi therapeutics at the forefront of precision medicine by discussing:

- Exploring AI-driven target discovery and combination therapies with CAR-T or radiotherapy to accelerate identification of disease-specific genes with high clinical relevance to enable faster precision RNAi therapy development
- Predicting future combination therapy strategies to stay ahead of emerging trends in multi-target silencing, for the expansion of treatment options for complex diseases
- Strategizing how to position pipelines at the forefront of next-gen RNAi innovation

Raj Reddy
Chief Executive Officer
Canary Cure

Mikko Turunen
Chief Scientific Officer
RNatives

David Jackson
Chief Executive Officer
Ceria Therapeutics

Alfica Sehgal
Chief Scientific Officer
Judo Biosciences

Mano Manoharan
Senior Vice President, Innovation Chemistry
Alnylam Pharmaceuticals

16.30 Chair's Closing Remarks & End of Conference Day Two

2026 Partners

Exhibition Partner

Headquartered in Morrisville, NC, USA, Synoligo Biotechnologies is a Contract Research and Development Organization (CRDO) specialized in manufacturing complex and highly modified oligonucleotide for academic, biotech start-up and large pharmaceutical communities. Synoligo is a leading oligonucleotide manufacturing company providing high quality, cost-effective custom oligonucleotides at varying scales for research, diagnostic, and therapeutic applications.

www.synoligo.com

Exhibition Partner

Established in 1981, ChemGenes has consistently provided the highest quality Phosphoramidites and Solid Supports in the market. Our Massachusetts facility is setup for therapeutic grade phosphoramidites for GMP grade oligonucleotide manufacturing. Furthermore, ChemGenes carries the widest variety of modified phosphoramidites and solid supports currently used in various areas of Nucleic Acid research. ChemGenes remains devoted to providing you with invaluable customer service and comprehensive technical support.

www.chemgenes.com

Event Partner

Sylentis is a European CDMO specializing in the development and manufacturing of therapeutic oligonucleotides. With nearly 20 years of experience and a state-of-the-art facility near Madrid, we offer flexible production capacity, advanced synthesis platforms, and robust analytical and regulatory support. Our integrated approach—from early development to regulatory submission—helps clients accelerate their path to market with confidence.

www.sylentis.com

Get Involved

Hannah Martin
Business Development Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Partnership Opportunities

7th Annual RNAi-Based Therapeutics Summit
January 27-29, 2026 | Boston, MA

Connecting RNAi Leaders Worldwide to Showcase Breakthroughs and Accelerate Innovation

As the premier industry-led forum dedicated to translating RNAi beyond the liver, the **7th RNAi-Based Therapeutics Summit** is the definitive meeting for **80+ senior leaders** from large pharma, innovative biotech, and investment firms driving the next wave of siRNA and miRNA drugs for neurology, cardiometabolic, oncology, and rare diseases. With a 40% attendance from VP-level and above, this is your exclusive platform to engage with key decision-makers.

Partner with this year's Summit if you want to:

Raise Your Brand Awareness

Position your company at the forefront of innovation by showcasing your technologies to the key opinion leaders and decision-makers who rely on specialized partners to solve critical challenges in extrahepatic delivery, novel chemistries, and scalable manufacturing.

Distinguish Your Solutions

Stand out by demonstrating your expertise in overcoming the unique hurdles of RNAi therapeutic development:

Advanced Delivery Platforms: Showcase your work in targeted conjugates (GalNAc and beyond), LNPs, exosomes, or novel modalities (e.g., DNA origami, antibody-oligonucleotide conjugates) for precise tissue targeting.

CMC & Manufacturing Excellence: Highlight your capabilities in oligonucleotide synthesis, lipid nanoparticle formulation, and analytical development to ensure purity, stability, and regulatory compliance.

AI-Driven Discovery: Demonstrate computational tools for target validation, predicting off-target effects, and designing next-generation RNAi structures.

Generate Commercial Opportunities

Capitalize on the immense deal-making momentum in the RNAi space, evidenced by Biogen's $1bn partnership with City Therapeutics and the rapid clinical progress of companies like Arrowhead and Alnylam. Connect with biotechs like Gensaic (AI-designed ligands), and Judo Biosciences (kidney-targeted STRIKE™ platform) who are seeking partners to accelerate their path to the clinic.

Access an Unmatched C-Suite Audience

Engage directly with the primary decision-makers. With 84% of speakers holding C-level positions, representing over 20 CXOs from leading RNAi biotechs. This summit offers unparalleled access to the executives who drive partnership and procurement strategies

What the Industry Is Searching For:

Extrahepatic Delivery:
Reliable platforms for targeted delivery to the CNS, muscle, adipose, kidney, and solid tumors to unlock new disease areas.

Scalable CMC Strategies:
Expertise in overcoming complex synthesis, encapsulation, and regulatory hurdles to ensure a smooth transition from clinical to commercial supply.

Novel Target Discovery & Validation:
AI-powered and data-driven approaches to identify and validate high-confidence targets in complex diseases beyond the liver.

Get Involved

Hannah Martin
Business Development Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

www.rnaibased-therapeutics.com/register/

Tel: +1 617 455 4188

Email: info@hansonwade.com

DISCOVER how pioneers like AbbVie, Biogen, and Sangene Bio are leveraging novel delivery platforms, from Trojan Horse BBB formulations and exosome-mediated delivery to AI-designed ligands and DNA origami, to unlock RNAi's potential in neurology, cardiometabolic, oncology, and rare diseases.

BUILD your strategy with exclusive insights on overcoming extrahepatic delivery barriers, optimizing CMC and regulatory pathways for scalable manufacturing, and harnessing AI for target discovery and lead candidate selection to de-risk your clinical translation.

ENGAGE with 80+ RNAi experts from top biotechs, Big Pharma dealmakers, and KOLs during dedicated networking sessions, interactive workshops on chemical engineering and in-silico strategies, and partner-led panels on investment and commercialization.

Drug Developer Pricing*	Register & Pay by Friday, November 7	On the Door Price
Conference + Workshop Day	$3,497 **(Save $700)**	$4,197
Conference Only	$2,599 **(Save $400)**	$2,999

Academic & Research Rate**	Register & Pay by Friday, November 7	On the Door Price
Conference + Workshop Day	$2,897 **(Save $700)**	$3,597
Conference Only	$2,199 **(Save $400)**	$2,599

Solution & Service Providers	Register & Pay by Friday, November 7	On the Door Price
Conference + Workshop Day	$4,397 **(Save $700)**	$5,097
Conference Only	$3,399 **(Save $400)**	$3,699

*To qualify for the drug developer rate your company must have a public drug pipeline and not provide fee-based services. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for academic and research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

Team Discounts***

- **10% discount – 2 Attendees**
- **15% discount – 3 Attendees**
- **20% discount – 4+ Attendees**

***Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

Venue

Wyndham Boston Beacon Hill
5 Blossom St, Boston, MA 02114
Wyndham Boston Beacon Hill | Boston Hotel | Official Site

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom